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ABSTRACT 
Background & Objectives: Quality of life (QOL) is impaired in end-stage renal disease 
patients, but the cause(s) is uncertain. To determine whether biomarkers of cardiac 
disease (TNT, NT-proBNP) were associated with change in QOL in the short (24 weeks) 
and long term (48 & 96 weeks) we studied 596 new hemodialysis patients without 
symptomatic cardiac disease followed for 2 years. 
Design, Setting, Participants & Measurements: Patients were enrolled in a double-
blind, randomized controlled trial to assess the impact of anemia correction with 
erythropoietin.  Change in QOL was measured using SF-36, FACIT Fatigue administered 
at 0, 24, 48 and 96 weeks, with pre-specified domains of interest being SF-36 Physical 
Functioning, SF-36 Vitality and FACIT Fatigue. In addition to baseline demographic and 
clinical characteristics, baseline biomarkers of cardiac disease and inflammation were 
assessed. 
Results:  The analysis plan pre-specified cut-off for baseline biomarkers as upper 
quartile. High Trop levels were independently and significantly associated with long term 
deterioration in all 3 domains. The adjusted B for change in physical function was -6.7 
(p=0. 035) at 48 weeks and -7.1(p=0.056) at 96 weeks; for change in vitality -
7.1(p=0.036) at 96 weeks; and for change in fatigue-6.2(p=0.035). 
Conclusions: In relatively healthy hemodialysis patients, high troponin T levels were 
associated with deterioration in physical function and vitality as well as increasing 
fatigue. 
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Chapter 1: INTRODUCTION 
 Chronic kidney disease is a global health problem with increasing incidence and 
prevalence rates being seen worldwide. In Canada between 1.3 million and 2.9 million are 
estimated to have chronic kidney disease (12.5% of the population) with 730 000 between 
stages 3-5 (Arora et al., 2013). This is comparable to the estimated prevalence of any 
stage of CKD in the United States (13.1%) and Australia (11.2%), but significantly higher 
than Europe (4.7 – 8.1%) and Asia (2.5 – 6.8%; Arora et al., 2013). There are also 
significant racial differences in the incidence and prevalence rates of chronic kidney 
disease with African-American and American Indian populations having an incident rate 
3.6 and 1.8 times higher, respectively, than Caucasians (Obrador & Pereira, 2014). The 
increased prevalence of chronic kidney disease worldwide is believed by some to be the 
result of advancements in treatment for chronic kidney disease that have been made over 
the last number of decades and the resultant increased survival of patients with end-stage 
renal disease (Obrador & Pereira, 2014). 
 Chronic kidney disease is a chronic deterioration of kidney function over time and 
can be the result of a number of causes. Diabetes and hypertension account for 44% and 
27.9% of all causes of incident ESRD, respectively (Obrador & Pereira, 2014; Levey & 
Coresh, 2012). However other potential causes include glomerulonephritis, polycystic 
kidney disease, urinary tract obstruction, reflux nephropathy, and drug-induced kidney 
problems (Kidney Foundation of Canada, 2014). Identifying the cause of CKD is 
important as it allows for targeted treatment and therapy to prevent and reduce further 
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kidney damage, as well as awareness of the implications it has on the rate of progression 
and risk of complications of the disease (Levey & Inker, 2014). 
Kidney Disease Improving Global Outcomes defines chronic kidney disease as 
“abnormalities of kidney structure or function, present for > 3 months, with implications 
for health.” Chronic kidney disease requires the presence of a decreased glomerular 
filtration rate (GFR) of < 60 mL/min/1.73 m2, or markers of kidney damage for greater 
than 3 months. Markers for kidney damage can include albuminuria (AER > 30 mg/24 
hours; ACR > 30 mg/g), urine sediment abnormalities, electrolyte and other abnormalities 
due to tubular disorders, abnormalities detected by histology, structural abnormalities 
detected by imagine, or history of kidney transplantation (Kidney Disease Improving 
Global Outcomes, 2013). 
End stage renal disease (ESRD) is defined as eGFR < 15 mL/min per 1.73m2 
(Kidney Disease Improving Global Outcomes, 2013). Dialysis improves blood volume 
and mineral/electrolyte levels and removes waste products from the blood. There are two 
types of dialysis used as treatments for kidney disease: hemodialysis and peritoneal 
dialysis. Hemodialysis functions by taking blood from the patient and passing it through a 
dialyzer where filtration occurs between the blood and dialysate, separated by an artificial 
membrane. The “cleansed” blood then passes back into the body’s normal circulation. 
Hemodialysis treatment is effective in relieving some symptoms of uremia. However a 
new lifestyle is necessary, including adherence to a strict diet, restriction of fluids, and 
use of a wide variety of medications. Peritoneal dialysis functions on the same principles 
as hemodialysis, however the blood is filtered by the provision of dialysate inside the 
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body. The peritoneal cavity is filled with the special dialysis fluid and the blood vessels 
filter wastes through the peritoneum and into the fluid. The fluid is drained via a catheter 
and replaced with new dialysis fluid several times daily (Kidney Foundation of Canada, 
2013).  
Quality of life represents a patient’s functioning, well-being and general health in 
physical, social, and psychological domains (Guyatt et al., 1993), and is a consistent 
predictor of mortality in patients suffering from ESRD (Lowrie et al., 2003; Lopes et al., 
2003; Kalantar-Zadeh et al., 2001). Patients with end-stage renal disease have 
consistently lower quality of life scores when compared to matched controls without 
ESRD, with the most significant differences occurring in physical function and vitality 
domains (Spiegel et al., 2008). A pronounced disparity is also evident in hemodialysis 
patients without prior symptomatic cardiac disease, who have greater health related 
quality of life as compared to hemodialysis patients with cardiovascular disease, but 
whose HRQOL is still impaired when compared to healthy individuals (Foley et al., 2009; 
Fukuhara et al., 2003). Cardiovascular events, specifically heart failure and 
atherosclerotic events have a significant impact on quality of life in hemodialysis patients 
(Briggs et al., 2013).  
Health related quality of life for this study was measured and assessed using a 
number of validated instruments, including the short-form health survey (Ware & 
Sherbourne, 1992; Fukuhara et al., 2003), the kidney disease quality of life questionnaire 
(Hays et al., 1994) and the functional assessment of chronic illness therapy measurement 
system (Webster et al., 2003). These instruments were all developed for self-
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administration by patients; however administration of the survey by a trained interviewer 
can reduce the burden for patients suffering from difficulty reading and severe fatigue. 
The surveys are scored according to the manuals provided and each raw score is 
transformed onto a 0 to 100 scale, with a higher value indicating a greater quality of life 
(Fukuhara et al., 2003; Webster et al., 2003; Hays et al., 1994; Ware & Sherbourne, 
1992). 
1.1 Study Objectives 
 The purpose of this study is to assess the predictive value of cardiac biomarkers 
for quality of life in hemodialysis patients without prior symptomatic cardiovascular 
disease. 
Specifically, the main objective is:  
1.) To determine whether the cardiac biomarkers, troponin T and N terminal pro-B type 
natriuretic peptide, predict deterioration in the physical domains (SF-36 Physical 
Function, SF-36 Vitality, FACIT Fatigue) of health related quality of life.  
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Chapter 2: LITERATURE REVIEW 
2.1 Search Strategy 
 A search was conducted through The National Library of Medicine using 
PubMed, Embase, The Cochrane Library and CINAHL with search terms pertinent to 
studies on cardiac biomarkers and their predictive value for quality of life in patients with 
chronic kidney disease. Experts in the field of nephrology known to the author were also 
asked for their opinions for search directions.  
 The literature search was limited to English language articles however it was not 
restricted by date to ensure the information for review would give a complete overview of 
the history of this illness and the progress made over time; the most recent articles (2000-
2014), however, were the main focus for information for this paper.  
 This literature review will offer background information on chronic kidney 
disease, specifically end-stage renal disease, as well as cardiac biomarkers and quality of 
life.  
2.2 Chronic Kidney Disease 
 While it is undisputed that the incidence and prevalence rates of chronic kidney 
disease are rising globally, it is challenging to determine the precise incidence of new-
onset kidney disease. The Framingham Offspring study examined 2585 participants free 
from pre-existing renal disease over a mean follow-up of 18.5 years and found that 9.4% 
(244 participants) had developed kidney disease, defined as eGFR < 64 and 59 mL/min 
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per 1.73 m2 for men and women, respectively (Fox et al., 2004). A retrospective cohort 
followed over a 5.5 year period, approximated the annual incidence of chronic kidney 
disease to be 1700 cases per million persons, with CKD defined as serum creatinine > 1.7 
mg/dL for six months or longer (Drey et al., 2003). It is important to note that the specific 
measure used to assess the presence of CKD (eGFR, serum creatinine) markedly 
influences the apparent incidence and prevalence of the disease. In a study by Turin et al., 
the lifetime risk of progressing to end-stage renal disease was calculated from a cohort of 
approximately 3 million Canadians. In participants free of ESRD at age 40, the lifetime 
risk of developing the disease is roughly 1 in 40 for men (2.66%) or 1 in 60 for women 
(1.76%). However as GFR decreases the risk for progressing to ESRD increases 
significantly (Turin et al., 2012). 
2.2.1 Etiology of Chronic Kidney Disease 
Chronic kidney disease is a chronic deterioration of kidney function over time and 
can be the result of a number of causes. As described by Levey et al. in the “Practice 
Guidelines for Chronic Kidney Disease”, kidney function begins at a “normal” level 
before increased risk factors lead to kidney damage resulting in a decreased GFR and 
ultimately kidney failure. While there is no one cause of kidney failure, there are 
numerous risk factors which can accelerate the damage to the kidneys and subsequent 
loss in function, which include susceptibility factors, initiation factors, progression factors 
and end-stage factors. Susceptibility factors increase the susceptibility and likelihood of 
the kidney being damaged. These factors include increasing age, a family history of renal 
disease or cardiovascular disease, racial and ethnic status, low birth weight and lower 
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socioeconomic status. Initiation factors directly damage the kidney and impair function 
and include diabetes, hypertension, systemic infections, urinary tract infections, 
obstructions and stones, and drug toxicity. Progression factors worsen an already 
damaged kidney leading to a greater and accelerated deterioration in function. These 
factors can include high levels of proteinuria, poor glycemic control for diabetics, 
smoking and hypertension.  End-stage factors are risk factors that increase the risk of 
death and impaired quality of life for patients in stage 5 CKD. These factors are 
centralized around dialysis treatment and include lower dialysis dose, vascular access 
type, anemia, low albumin and late detection and referral (Levey et al., 2003). 
2.2.2 Classification of Chronic Kidney Disease 
Glomerular filtration rate represents the volume of blood filtered from the 
glomerular capillaries into Bowman’s space per unit time, with a decreasing GFR 
representing impaired kidney functioning. While normal GFR varies amongst individuals 
based on age, sex, nutritional status and race, it is still considered the best index of overall 
kidney function (Levey & Inker., 2014). Albuminuria is most often indicated by an 
elevated albumin-to-creatinine ratio (ACR), and indicates an increased permeability of 
the glomerulus to large proteins and macromolecules, resulting from primary or 
secondary kidney disease (Remuzzi et al., 2006).  
Staging of Chronic kidney disease is based on assigning the cause of CKD, 
assigning the GFR to one of six stages, and classifying albuminuria into one of three 
categories, which would then serve as a guide for clinical treatment and management. The 
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cause of CKD is assigned based on the “presence/absence of systemic disease and the 
location within the kidney of observed or presumed pathologic-anatomic findings” 
(Kidney Disease Improving Global Outcomes).  
The glomerular filtration rate is classified into categories ranging from G1 to G5, 
reflecting the level of impairment. Stage one (G1) is defined by a normal GFR (>90 
mL/min per 1.73 m2) representing normal or high kidney function, stage two (G2) CKD 
mildly decreased function with a GFR between 60-89 mL/min per 1.73 m2, stage three is 
subdivided into G3a and G3b, with G3a (mildly to moderately decreased) having a GFR 
between 45-59 mL/min per 1.73 m2, and G3b (moderately to severely decreased) having a 
GFR of 30-44 mL/min per 1.73 m2. This subdivision is intended to outline the 
relationship between a decreasing GFR and the subsequent increased risk for adverse 
events and mortality that is associated with it. Stage four (G4) has severely decreased 
renal function with a GFR between 15-29 mL/min per 1.73 m2, and stage five (G5) or 
end-stage renal disease is a GFR less than 15 mL/min per 1.73 m2 indicating kidney 
failure (Kidney Disease Improving Global Outcomes).  
Since the original KDOQI classification scheme was published in 2002, 
albuminuria staging has been added to CKD staging based on evidence of an increased 
risk of mortality or progression to ESRD at high levels of albuminuria, independent of 
GFR. Stage one of albuminuria (A1) is defined as an ACR< 30 mg/g and is considered 
normal to mildly increased. Stage two (A2) is moderately increased with an ACR of 30-
300 mg/g, with stage three (A3) being an ACR of >300 mg/g or severely increased. If an 
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albuminuria measurement is unavailable it can be substituted for urine reagent strip 
results (Kidney Disease Improving Global Outcomes).  
2.3 Quality of Life 
2.3.1 Short Form-36 (SF-36) 
The Short-form health survey was developed as an instrument to assess quality of 
life in clinical practice and research by examining and assessing eight health concepts. 
The SF-36 survey is divided into two summary scores, physical component score (PCS) 
and mental component score (MCS), and comprised of eight sub-scales: PCS – physical 
functioning, physical role limitations, bodily pain, general health, vitality; MCS – 
emotional role limitations, emotional well-being, and social functioning (Lopes et al., 
2007; Fukuhara et al., 2003). 
The usefulness and validity of the SF-36 as a tool for assessing quality of life has 
been demonstrated and supported by numerous studies. Research by McHorney et al. 
tested the instruments validity using psychometric and clinical criteria. The results from 
traditional psychometric and clinical tests of validity were compared and a principal 
component analysis was used to test the hypothesized domains of physical and mental 
health. Results from this study supported the validity of using the SF-36 for examining 
physical health, mental health, social functioning, vitality and general health (McHorney 
et al., 1993). Other research has confirmed the instruments use and validity specific to the 
hemodialysis population with a cross sectional study by Wight et al. of 660 end stage 
renal disease patients concluding that the SF-36 is a practical and consistent questionnaire 
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and there is evidence supporting its construct validity (Wight et al., 1998). This notion is 
further supported by Lowrie et al., who collected cross sectional data on 13,952 prevalent 
dialysis patients to examine whether the physical and mental component summary scores 
of the SF-36 were predictive for morbidity and mortality. The results of this study 
indicated that even after adjusting for clinically relevant factors, the PCS and MCS of the 
SF-36 were powerfully predictive for morbidity and mortality in the dialysis population 
(Lowrie et al., 2003). 
In the SF-36 domain of physical function, the mean score in the general 
population was 86, for dialysis patients it was 41 (Hopman et al., 2000; Fukuhara et al., 
2003), and for the hemodialysis patients without symptomatic cardiac disease it was 67 
(Foley et al., 2009). For the vitality domain of SF-36, the score for the general population 
was 66 (Hopman et al., 2000), for dialysis patients it was 43 (Fukuhara et al., 2003), and 
for hemodialysis patients without symptomatic cardiac disease 58 (Foley et al., 2009). 
2.3.2 Kidney Disease Quality of Life Questionnaire (KDQOL) 
The kidney disease quality of life questionnaire is a longer survey that targets 
health related concerns of patients suffering from kidney disease. The KDQOL is 
centralized around the SF-36, with 36 generic items, however it also examines 43 kidney 
disease specific items, producing 11 scales specific for kidney disease including: 
symptoms, effects of kidney disease on daily life, burden of kidney disease, work status, 
cognitive function, quality of social interaction, sexual function, sleep, dialysis staff 
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encouragement, social support and patient satisfaction (Lopes et al., 2007; Hays et al., 
1994).  
The use of KDQOL as an instrument for examining quality of life has been 
validated in numerous studies. Research by Hays et al. examined 165 individuals with 
kidney disease across nine dialysis units in the United States and found internal 
consistency reliability exceeding 0.75 for every measure except one supporting the 
reliability and validity of the KDQOL (Hays et al., 2004). A study by Kurella et al. was 
conducted to validate the cognitive function subscale of the KDQOL. The KDQOL was 
administered to 157 patients with varying levels of CKD (79 with ESRD) and compared 
their results in the cognitive function subscale to results obtained from the gold standard 
test, the Modified Mini-Mental State Exam. Results from this study showed direct 
correlation between the KDQOL scores and the Mini-Mental State Exam, which led to 
the conclusion that the KDQOL is a valid instrument for estimating cognitive function in 
dialysis patients (Kurella et al., 2004).  
2.3.3. Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue) 
  The functional assessment of chronic illness therapy measurement scales are 
instruments targeted to measuring quality of life in patients suffering from chronic 
illnesses including cancer, multiple sclerosis, HIV, renal disease, amongst others. There 
are roughly 50 different generic and targeted questionnaires, including that for fatigue. 
Raw scores are automatically converted via statistical software packages into scales with 
higher values indicating a better quality of life (Webster et al., 2003). 
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While not specifically validated for chronic kidney disease, this instrument has 
been validated for patients with similar levels of quality of life. Chandran et al. reported 
the validity of the FACIT-Fatigue questionnaire in psoriatic arthritis patients with an 
internal consistency score 0.96. Scores were found to be reproducible and correlated with 
other fatigue instruments that were used (Chandran et al., 2007). This result is consistent 
with findings from a study be Yellen et al. who measured fatigue and other anemia-
related symptoms using the FACT-Fatigue. Yellen et al. demonstrated stable scores (test-
re-test r=0.87) and internal consistency (coefficient alpha range = 0.95-0.96) of the 
FACT-Fatigue instrument when assessing fatigue among cancer patients. Although not 
specifically validated for chronic kidney disease, this instrument has been demonstrated 
to be valid and reliable for many other chronic illnesses and has been utilized previously 
for CKD patients (Parfrey & Wish, 2010). 
The FACIT fatigue mean score in the general population was 80 and in diabetic 
chronic kidney disease patients was 30 (Lewis et al., 2011), as compared to 70 for 
hemodialysis patients without symptomatic cardiac disease (Foley et al., 2009).  
 
2.4 Cardiac Disease and ESRD 
 Cardiovascular disease is an important cause of morbidity and mortality in end-
stage renal disease patients, accounting for approximately fifty percent of deaths amongst 
patients on maintenance hemodialysis (Henrich, 2014), and a mortality rate approximated 
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to be 10 to 100-times higher than age, gender and race matched controls (Wang & Lam, 
2012).  
 Cardiac disease may be caused by vascular disease (atherosclerotic coronary 
artery disease or microvascular disease), predisposing to myocardial infarction/angina, or 
by cardiomyopathy (diastolic or systolic dysfunction) predisposing to heart failure 
(Parfrey et al., 2005). 
Cardiovascular disease is the leading cause of death for CKD patients, however 
the relationship between traditional risk factors (ie: blood pressure, serum LDL 
cholesterol) and death is complex, with risk at both the highest and lowest levels, 
potentially indicating confounding by disease severity, malnutrition and inflammation, or 
unmeasured comorbidities (Levey & Coresh, 2012). According to the National Kidney 
Foundation practice guidelines, “Cardiovascular disease deserves special consideration as 
a complication of chronic kidney disease because CVD events are more common than 
kidney failure in patients with stage G3 (and a small extent stage G4) chronic kidney 
disease; CKD seems to be a risk factor for cardiovascular disease; and CVD in patients 
with CKD is treatable and potentially preventable” (Levey et al., 2003). According to 
Levey & Coresh, several studies have shown that “low GFR and high albuminuria are 
associated with an increased risk of cardiovascular mortality, de-novo and recurrent 
cardiovascular events, and subclinical cardiovascular disease.” The pathophysiological 
links between chronic kidney disease and cardiovascular disease include a number of 
traditional and non-traditional risk factors: hypertension; fluid overload; electrolyte, acid-
base and mineral disorders; anemia; dyslipidemia; inflammation; increased oxidative 
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stress; and prothrombotic stimuli, but could also be the result of reverse causation as 
CVD is recognized as a risk factor for deteriorating GFR (Levey & Coresh., 2012). 
Myocardial dysfunction is common just prior to commencing dialysis and its 
prevalence increases after treatment onset (Henrich, 2014). A study of 432 patients with 
chronic kidney disease showed that 31% had evidence of heart failure just prior to 
beginning dialysis treatment, and once treatment began, an additional 25% developed 
heart failure at a rate of 7% annually (Harnett et al., 1995).  In addition, a study 
examining 596 incident hemodialysis patients without symptomatic heart disease found 
that 75% of patients starting hemodialysis had left ventricular hypertrophy, 32% had left 
ventricular dilatation and 15% had systolic dysfunction (Foley et al., 2009). 
Cardiovascular events, particularly heart failure and atherosclerotic events have a major 
impact on HRQOL in ESRD. Hemodialysis patients who have not experienced these 
events may have elevated troponin T, a marker of myocardial injury, or elevated BNP, a 
marker of left ventricular wall stress, which may have predictive value for later outcomes 
(Foley et al., 2010).    
 
2.5 Cardiac Biomarkers 
 The World Health Organization defines a biomarker as “almost any measurement 
reflecting an interaction between a biological system and a potential hazard, which may 
be chemical, physical or biological. The measured response may be functional and 
physiological, biochemical at the cellular level or a molecular interaction” (Strimbu & 
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Tavel, 2010). Biomarkers are commonly used now in clinical research and are often the 
primary end points in clinical trials. More than that, many biomarkers have been validated 
and characterized as consistent predictors for a variety of clinical outcomes in differing 
populations. For a biomarker to be clinically useful it has to be: accurate; easily 
accessible; inexpensive to measure; reproducible; easy to interpret; have a defined 
“normal” value or range; have high sensitivity and specificity in detecting the condition; 
and knowledge of the biomarker levels must impact the management of the condition 
(Wang & Lam, 2012).  
Cardiac biomarkers are biomarkers that are specifically used to assess the function 
and health of the heart, can be used to assess damage and injury, and to stratify patients 
into risk categories. Troponin T and brain natriuretic peptide are two such commonplace 
biomarkers, with troponin T functioning as a marker of myocardial injury, and BNP 
serving as a marker of left ventricular wall stress (Foley et al., 2010). Thus measuring 
cardiac biomarkers that reflect cardiac injury and dysfunction have clinical value in 
potentially facilitating the early detection of diseased patients for early treatment (Wang 
& Lam, 2012). 
2.5.1 Troponin T 
  Troponin is an accessory protein that plays a fundamental role in the contraction 
of skeletal and cardiac muscle fibres. Troponin is bound to the actin filament of muscle, 
and in conjunction with tropomyosin, these proteins regulate muscle contraction (Cooper, 
2000). Troponin is a complex composed of three components (Troponin C, Troponin I, 
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Troponin T), each with a unique and specific function.  Troponin C is the calcium binding 
component of the troponin complex, troponin I inhibits the ATPase activity of 
actomyosin, and troponin T is responsible for the binding of tropomyosin to the troponin 
complex (Filatov, 1999). The contraction of muscle fibres is triggered by nerve impulses, 
which subsequently causes the release of calcium into the cytosol from the sarcoplasmic 
reticulum. When calcium concentrations are high, the binding of calcium with troponin C 
causes the troponin-tropomyosin complex to shift, relieving the inhibition of troponin I 
thus allowing the muscle to contract.  When calcium concentrations are low, the troponin-
tropomyosin complex blocks the interaction of actin and myosin and inhibits the 
contraction (Cooper, 2000). Approximately 7% of cardiac troponin T exists freely 
circulating in the myocyte, with the rest remaining bound within the sarcomere. Upon 
myocardial injury, troponin T is released from the damaged myocardium into the 
circulation. The degree of cardiac troponin T elevation correlates with the size of the 
infarct indicating the severity of damage to the myocardium. Cardiac troponin levels are 
currently the gold standard test for diagnosing acute myocardial infarction, and are 
important for risk stratification and prognosis (Wang & Lam, 2012).  
After an extensive review of the literature examining health databases including 
PubMed, Embase and The Cochrane Library using the search terms “troponin t”, “quality 
of life” and “chronic kidney disease”, no literature was found specifically examining 
troponin T levels and its predictive value for quality of life in patients with chronic 
kidney disease or ESRD. There is however, a wealth of research that exists examining the 
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prognostic value of troponin T for cardiac death and all-cause mortality as well as the risk 
of occurrence of cardiovascular events, some of which is discussed below. 
For patients with ESRD, cardiac troponin T is often elevated without the presence 
of symptomatic cardiac disease or injury, potentially detecting subclinical cell injury due 
to the stresses invoked by hemodialysis (Khan et al., 2005). Research conducted by Wang 
et al., 2007 demonstrated that even minimally increased troponin levels have important 
clinical consequences as dialysis patients with cardiac troponin levels between 0.01 and 
0.1 ng/ml have increased risk for mortality and adverse cardiovascular events compared 
to those with undetectable levels, and those with a troponin T >0.1 ng/ml are typically the 
sickest patients with the worst outcomes (Wang et al., 2007). Thus any degree of troponin 
elevation represents some degree of injury and is associated with increased risk of a 
cardiovascular event and death.  
 A systematic review by Khan et al. examined the prognostic value of troponin T 
and I for patients with end-stage renal disease who were asymptomatic for cardiovascular 
disease. The meta-analysis selected 28 studies (3931 asymptomatic ESRD patients) that 
met the explicit inclusion and exclusion criteria and examined whether elevated troponin 
T levels was predictive for cardiac death. From the pooled analysis specifically 
examining troponin T and all-cause mortality (17 studies), elevated troponin T was 
significantly associated with increased all-cause mortality with a relative risk score of 
2.64 and a 95% C.I. of 2.17 to 3.20.  Khan and colleagues also examined troponin and 
cardiac death (via 8 studies) and revealed that elevated troponin T was strongly associated 
with cardiac death over the long-term (RR 2.55, 95% CI 1.93 to 3.37, p<0.001).  Of the 
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16 studies that controlled for other prognostic factors (age, diabetes, presence of 
cardiovascular disease, left ventricular hypertrophy and left ventricular dysfunction), 15 
demonstrated an independent association between elevated troponin T and all cause 
mortality (Khan et al., 2005).  
 A study conducted by Apple and colleagues, examined the predictive value of 
troponin T for subsequent death in 733 ESRD patients. Elevated troponin T was defined 
for the study using the 99th percentile of a healthy reference population (> 0.01 ng/ml). Of 
the 733 patients, 82% of unselected asymptomatic ESRD patients had a level above this 
value and it was found that with adjustment for other significant risk factors for mortality 
(age, history of cardiovascular disease and dialysis duration), elevated troponin T 
increased the risk of death 2- to 4-fold, and this increased risk of death was maintained 
over a 1, 2 and 3 year follow-up (Apple et al., 2002).  
2.5.2 Brain Natriuretic Peptide 
 After an extensive review of the literature examining health databases including 
PubMed, Embase and The Cochrane Library using the search terms “brain natriuretic 
peptide”, “NT-proBNP”, “quality of life” and “chronic kidney disease”, no literature was 
found specifically examining NT-proBNP levels and its predictive value for quality of life 
in patients with chronic kidney disease or ESRD. There is however research that exists 
examining the prognostic value of BNP for cardiac death and all-cause mortality which 
will be briefly discussed. 
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The heart secretes two major hormonal natriuretic peptides to re-establish blood 
volume homeostasis: atrial natriuretic peptide (ANP) and brain natriuretic peptide. Brain 
natriuretic peptide is synthesized by the ventricles of the heart and functions in response 
to myocardial stretch to cause vasodilation, natriuresis and inhibition of the renin-
angiotensin system. It is initially synthesized from ventricular myocytes as an amino acid 
precursor and via intracellular modification, forms a 108-amino acid pro-BNP hormone. 
This hormone is subsequently cleaved to form a 32-amino acid activated C-terminal 
fragment (BNP) and an inactive 76-amino acid N-terminal fragment (NT-proBNP). NT-
proBNP is largely eliminated by the kidneys and with a half-life of approximately 120 
minutes, circulates in concentrations roughly 6 times that of BNP and is cleared by 
enzymatic degradation with a half life ~ 20 minutes (Wang & Lam, 2012). The precise 
impact of chronic kidney disease on circulating BNP and NT-proBNP levels is uncertain 
and continues to be debated, however given that N-terminal fragment is primarily 
excreted by the kidneys, increased NT-proBNP could potentially be a proxy for residual 
renal function, a known predictor of morbidity and mortality. These levels are almost 
invariably elevated in ESRD patients, and increased serum concentrations are highly 
predictive for cardiac death in many cardiovascular disease states (Tagore et al., 2008).  
 NT-proBNP elevation in dialysis patients is primarily the result of increased LV 
systolic and diastolic wall stress, however other mechanisms have been supported as well. 
Research exists indicating a number of other possible mechanisms for NT-proBNP 
elevation including: LV end-systolic wall stress; myocardial hypoxia which up-regulates 
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BNP gene expression; and the high prevalence of LV structural and function 
abnormalities in dialysis patients (Wang & Lam, 2012). 
 In a study conducted by Gutierrez et al., NT-proBNP levels were assessed at 
baseline and serially thereafter in 2990 incident hemodialysis patients. The prognostic 
value of these NT-proBNP levels for all-cause mortality and cardiovascular mortality was 
determined. The quartiles of NT-proBNP levels were examined (quartile 3: 5111 – 14,100 
ng/L; quartile 4: > 14,100 ng/L), and the one-year mortality rate for the upper quartile 
was 37.9 deaths per 100 patient-years risk, and 21.2 deaths per 100 patient-years risk in 
the third quartile. They also reported that increasing quartiles of NT-proBNP was 
associated with 90 day and 1 year all-cause and cardiovascular mortality and remained 
significantly independently associated when adjusted for case-mix and laboratory values 
(Gutierrez et al., 2008).  
 In a study conducted by Apple et al., 399 end-stage renal disease patients were 
enrolled to assess the predictive power of hsCRP, cTNT, cTNI and NT-proBNP for all 
cause mortality. The analysis for NT-proBNP was completed using both the normal cut-
off (97.5th percentile – patients aged <75 was 125 ng/L;  >75 years was 450 ng/L) and 
again using tertiles, as 99% of the population had levels greater than the normal cut-off. 
This finding is likely due to the reliance on renal excretion for NT-proBNP, thus 
individuals with impaired renal function would have impaired NT-proBNP excretion, and 
hence the elevated levels. The results from this study showed no significant prognostic 
value for NT-proBNP and mortality using the normal cut-off (97.5th percentile) for NT-
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proBNP levels, however did demonstrate significance using the upper tertiles (Apple et 
al., 2004).  
2.6 Other Factors Influencing Quality of Life in End-Stage Renal Disease 
 Health related quality of life is impaired in hemodialysis patients, and can be 
influenced by a number of factors including but not limited to: age, hemoglobin level, 
socioeconomic status, literacy, dialysis program, ethnic groups, sex, mobility, 
comorbidities, nutritional status, depression and unsuccessful previous renal transplant 
(Annees et al., 2014).   
After an extensive review of the literature examining health databases including 
PubMed, Embase and The Cochrane Library using a combination of the search terms 
“age”, “hemoglobin”, “demographics”, “predictors”, “quality of life” and “chronic kidney 
disease”, a variety of literature was found that highlighted several factors and their 
influences on quality of life in hemodialysis patients.  
Morsch et al. conducted a descriptive cohort study on 40 hemodialysis patients to 
assess the effect of socio-demographic variables, diabetes, and clinical indicators on 
quality of life as assessed by the SF-36. Morsch and colleagues discovered that being 
male was significantly associated with improved quality of life in the energy/fatigue 
domain and that diabetic patients had a significantly worse perception of quality of life 
than non-diabetic patients in the SF-36 Physical Function domain. Morsch et al. also 
discovered a correlation between serum albumin (p<0.05), end-stage renal disease 
severity index (used to assess comorbidity aspects: cardiovascular, cerebrovascular, 
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peripheral vascular disease, peripheral neuropathy, bone disease, respiratory disease, 
deficient vision, autonomic neuropathy and gastro- intestinal disease, dialytic access and 
events, diabetes and an open category; p<0.001) and hematocrit (p<0.05) with physical 
function. No correlations were found for the energy/fatigue domain (Morsch et al., 2006). 
In a study conducted by Bayoumi et al., 100 hemodialysis patients across three 
hemodialysis units in Saudi Arabia were followed for one year to assess what factors 
were associated with quality of life using the SF-36 and KDQOL. Researchers found a 
significant association between employment status and education with quality of life in 
the univariate analysis but these associations were lost in multivariate modelling. The 
significant and independent factors associated with worsened quality of life per the 
multivariate model were increasing age, increasing dialysis duration and being male. 
While the majority of the literature is in agreement with these findings, there is some 
debate over the gender impact, with other research indicating that males have a better 
quality of life in some domains (Morsch et al., 2006). This contradicting result is believed 
to be the result of the cultural role of the male in Saudi society, and the subsequent 
increased perception of impairment in daily function thus deteriorating quality of life 
(Bayoumi et al., 2013).  
 A systematic review by Spiegel et al. (2008) investigated 47 articles to determine 
the predictive value of a variety of biomarkers (dialysis adequacy, anemia, nutritional, 
mineral metabolism, inflammation) for quality of life in hemodialysis patients.  
Differences in quality of life scores between groups were measured using a scaled effect 
size (ES), which allowed the researchers to compare quality of life outcomes in different 
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interventions using the same uniform ES. The range of ES scores was standardized, and 
each biomarker was stratified as “high” or “low” as defined by the literature. The author’s 
results concluded that patients with end stage renal disease have consistently lower 
quality of life scores as compared to healthy controls, especially in the physical function 
and vitality areas, with less impact being detected on mental health. The effect of dialysis 
adequacy, anemia, nutritional, mineral metabolism and inflammation biomarkers on 
quality of life was found to be mostly insignificant, with only serum albumin and serum 
creatinine biomarkers having a significant result, consistently providing the largest 
change in SF-36 scores, while hematocrit levels were only weakly related (Spiegel et al., 
2008).  
2.7 Study Rationale 
 Patients with end-stage renal disease have diminished scores in the physical 
domains of health related quality of life. Nutritional biomarkers have been shown to be 
significantly associated with this impairment; however there is a poor association 
between biomarkers for dialysis adequacy, mineral metabolism and inflammation with 
changes in quality of life scores (Spiegel et al., 2008).   
 Cardiovascular disease is the leading cause of death for hemodialysis patients and 
studies have shown the predictive value of cardiac biomarkers (troponin T and NT-
proBNP) for all-cause mortality (Khan et al., 2005; Gutierrez et al., 2008). Despite this 
known relationship, no research exists that examines the predictive value of elevated 
cardiac biomarkers for change in the physical domains of quality of life over time. 
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Hemodialysis patients without prior symptomatic cardiovascular disease may still present 
with elevated baseline troponin T and BNP levels (Foley et al., 2010). This study 
examines the association between elevated baseline cardiac biomarkers and change in 
quality of life over time across the SF-36 Physical Functioning, SF-36 Vitality and 
FACIT Fatigue domains of health related quality of life. 
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Chapter 3: RESEARCH METHODS 
3.1 Patients and Methods 
 Incident hemodialysis patients without symptomatic cardiac disease and left 
ventricular dilation were identified and recruited for participation from one of 95 
treatment centers located throughout Canada and Europe to assess the impact of varying 
degrees of correction of anemia with erythropoietin via a randomized trial. Patients were 
deemed eligible for participation if they met the following inclusion criteria: (a) 
predialysis hemoglobin levels between 8 and 12 g/dl, (b) hemodialysis commenced in the 
preceding 3 to 18 months, (c) 18 years of age or older, (d) left ventricular volume index 
(LVVI) < 100 ml/m2 on screening echocardiography (normal < 90 ml/m2 ), and (e) 
predialysis diastolic blood pressure <100 mmHg. Exclusion criteria were as follows: (a) 
clinical evidence or history of symptomatic cardiac failure or ischemic heart disease, (b) 
daily prednisone dosages >10 mg, (c) medical conditions that are likely to reduce epoetin 
responsiveness, including uncorrected iron deficiency; concurrent malignancy; blood 
transfusion in the preceding month; therapy with cytotoxic agents; seizure in the 
preceding year; hypersensitivity to intravenous iron; and current pregnancy or 
breastfeeding. Between February 2000 and June 2001, 596 patients enrolled in the study 
with 30% of participants from Canada, and the remaining 70% from one of nine 
European countries (Austria, Belgium, France, Germany, Greece, Hungary, Poland, 
Spain, and United Kingdom). Dr. Patrick S Parfrey centrally monitored the Canadian 
participants from St. John’s, Canada and the European participants were centrally 
monitored from Manchester, England by Dr. Robert N Foley (Parfrey et al., 2005).  
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Patients were randomized via an interactive voice randomization telephone 
system, using permuted blocks and stratifying by gender and epoetin α use, to either the 
higher hemoglobin target (13.5 to 14.5 g/dl) or lower hemoglobin target (9.5 to 11.5 g/dl). 
Consequently for the purpose of this thesis all patients were included as one cohort. 
Patients were masked to treatment assignment, as were their doctors. A 24 week titration 
period was implemented to achieve appropriate hemoglobin targets followed by a 72 
week maintenance period. Hemoglobin levels were achieved and maintained via epoetin 
α, using a predefined algorithm to calculate the required dosage (150 IU/kg per week for 
the higher target group). For patients whose hemoglobin levels diverged from the target, 
epoetin α dosage was modified by 25% (25 IU/kg) of the previous dose to correct for the 
difference. Epoetin α was administered subcutaneously and intravenously until August 
22nd, 2002, at which point a study amendment restricted the administration of the drug to 
intravenous only. For the duration of the study, a form was faxed weekly to the 
coordinating centers for each patient detailing hemoglobin levels, epoetin α regimen, 
blood pressure, and transferrin saturation. In response to the patient information, weekly 
treatment recommendations were faxed back to treatment centers (Parfrey et al., 2005).  
Patients were asked to provide a medical history and consent to the collection and 
administration of tests to obtain baseline evaluations of vital signs, height, weight, blood 
chemistry, M-mode echocardiography, electrocardiography, and a 6-min walking test. In 
addition to demographic factors (age, gender, and race), baseline clinical characteristics 
(diabetes, primary renal disease, dialysis vintage, blood pressure, body mass index, type 
of vascular access) were recorded, as were conventional laboratory test results (Hb, white 
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cell count, percentage of iron saturation, urea reduction ratio, and serum albumin) and 
other serologic tests at baseline. Serum concentrations of BNP and TNT were measured 
in 2009 using diagnostic kits analyzed on an Elecsys 2010 immunochemistry analyzer 
(Roche Diagnostics, Montreal, Quebec, Canada). Serum high-sentivity C-reactive protein 
was measured using CRP reagent and performed on an IMMAGE Immunochemistry 
system, and Serum IL-6 kits were used with a Unicel DxI 800 Access Immunoassay 
system to measure serum IL-6 levels (Beckman Coulter, Fullerton, CA). Serum leptin 
was measured by ELISA technique using kits purchased from Diagnostic Systems 
Laboratories, Inc (Webster, Tx). Prior to analysis, blood samples were stored securely 
with researchers at a temperature of minus 80 degrees Celsius (Foley et al., 2010). 
Quality of life was assessed using two validated instruments, the Medical 
Outcomes Study Short Form-36 and the functional assessment of chronic illness therapy 
fatigue scale (Hays et al., 1997; McHorney et al., 1994; Jhamb et al., 2008) with pre-
specified domains of interest for analysis: physical function and vitality measured using 
the SF-36 questionnaire and fatigue using the FACIT fatigue questionnaire. A-priori 
short-term change in HRQOL was defined as the change from baseline to the assessment 
at 24 weeks, and long-term change as the change from baseline to the assessment made at 
48 and 96 weeks. These tools were administered to patients at weeks 0, 24, 48, and 96.  
There was no difference in the clinical or demographic characteristics or in 
treatment assignment of those who had only one KDQOL assessment (n=12) and those 
who had serial assessments (n=484). At each assessment, > 90% of patients remaining in 
the study completed the questionnaire.  
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 Ethics approval for this study was obtained from local research ethics review 
boards prior to the study being initiated. All patients provided informed consent, and the 
research was conducted in accordance with Good Clinical Practice guidelines, 
Declaration of Helsinki and the Tri Council Policy Statements for conducting research on 
humans. The last patient completed this study in May 2003. 
3.2 Statistical Analysis 
 Data were coded and entered into the Statistical Package for the Social Sciences 
(SPSS) for analysis (IBM, 2010). Baseline characteristics were described by number (%) 
or by median with interquartile range. For the cardiac and inflammatory biomarkers, a 
priori it was specified that high levels were above the 75th percentile. 
 Univariate linear regression was conducted to assess the association between the 
baseline variables and baseline health-related quality of life scores and change in scores 
over time. The independent variables included in the univariate analysis were selected 
based on potential associations with quality of life after consulting the literature. All 
clinically significant biomarkers (p <0.05) were included in the multivariate models along 
with all cardiac biomarkers of interests. The change in quality of life over time variable 
was computed by calculating the difference in quality of life scores for each patient at 24 
weeks and baseline, 48 weeks and baseline and 96 weeks and baseline. This change 
variable was then included in the analysis as the dependent variable. These outcome 
variables were examined graphically and appeared fairly normally distributed and no 
further transformation was required prior to statistical analysis. For each analysis missing 
data was handled using listwise deletion, with checks conducted to ensure that the sample 
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size was adequate to preserve significance and power for each individual model. Multiple 
linear regression models were constructed using the enter method and it was pre-specified 
that these include variables which were associated with the outcome at p <0.05 in the 
univariate analysis. Multivariate models were also created to assess the impact of 
troponin T and NT-proBNP levels on change in quality of life independent of age, sex, 
diabetes and baseline HRQOL score. General linear models for repeated measures were 
also performed to demonstrate the association between elevated troponin T levels and 
change in quality of life across the three domains.  
 Repeated measures ANOVA was conducted to supplement and confirm the results 
obtained from the multivariate regression models. Repeated measures ANOVA is 
appropriate for analysis when there are repeated measurements that are assumed to be 
correlated within a subject, in this case quality of life scores over time. This statistical test 
is similar to multivariate regression models in that it provides the association between the 
independent variables and the dependent, however the repeated measures ANOVA allows 
for increased precision since sources of variability between subjects is removed. Repeated 
measures ANOVA does however require more subjects to maintain power, hence the 
results can be significantly influenced by missing data (Laerd Statistics, 2013).  
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Chapter 4: RESULTS 
There were a total of 596 new hemodialysis patients without symptomatic 
cardiovascular disease enrolled in this study across 95 treatment centers in 10 countries 
between 2000 and 2001 with the last patient completing the study in May 2003. Linear 
regression and ANOVA models were used to analyze the predictive value of cardiac 
biomarkers for quality of life over time.  
Table 1 shows the baseline characteristics for the study population. The median 
age was 51.5 years, 39.6% of participants were female, and 10.6% were non-Caucasian. 
Only 17.8% had diabetes as the cause of end-stage renal disease, and patients with a 
history of cardiovascular disease were excluded. All patients enrolled had commenced 
dialysis between 3 and 18 months prior to the start of the study, and the median time on 
dialysis was 9 months. Of the 596 participants, 502 (84.2%) had a fistula as vascular 
access. The upper quartile for troponin T was > 0.051 ng/ml (N=118), and for NT-
proBNP it was > 651.9 pg/ml (N=120). The median score for SF-36 Physical Functioning 
was 70, for SF-36 Vitality it was 55 and for FACIT Fatigue it was 73.1.  
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Table 1:Baseline demographic and clinical characteristics, biomarkers and HRQOL 
scores 
Age (yrs); median (25th to 75th percentiles) 51.5 (39 to 62) 
Female; N (%) 236 (39.6) 
Non-White Race; N (%) 63 (10.6) 
Cause of ESRD: 
     Glomerulenephritis; N (%) 
     Diabetic Nephropathy; N (%) 
     Polycistic Kidney Disease; N (%) 
     Hypertension; N (%) 
     Other/Unknown; N (%) 
 
171 (28.7) 
106 (17.8) 
54 (9.1) 
48 (8.1) 
217 (36.4) 
Dialysis Duration (mo); median (25th to 75th percentiles) 9 (6 to 14) 
Dialysis Access: 
     Fistula; N (%) 
     Graft; N (%) 
     Catheter; N (%) 
 
502 (84.2) 
33 (5.5) 
61 (10.2) 
Assigned to High Hb Target; N (%) 296 (49.7) 
Epoetin Dosage (U/wk); median (25th to 75th percentiles); n=584 6000 (4000 to 8000) 
BMI (kg/m2); median (25th to 75th percentiles) 25.5 (22.6 to 29.3) 
Systolic BP (mmHg); median (25th to 75th percentiles); n=595 140 (130 to 158) 
Diastolic BP (mmHg); median (25th to 75th percentiles); n=596 80 (71 to 90) 
Hemoglobin (g/dl); median (25th to 75th percentiles); n=580 11 (10.2 to 11.7) 
Serum Albumin (g/L); median (25th to 75th percentiles); n=588 40 (38 to 41) 
Urea Reduction Ratio (%);median (25th to 75th percentiles); n=572 67 (60 to 72.5) 
Biomarkers; median (25th to 75th percentiles)  
Cardiac:  
     Troponin T (ng/ml); n=481 
     NT-proBNP (pg/ml); n=481 
 
0.021 (0.009 to 0.051) 
289.2 (137.3 to 651.9) 
Inflammatory: 
     C-Reactive Protein (mg/L); n=481 
     IL-6 (pg/ml); n=481 
 
3.47 (1.47 to 8.13) 
4.39 (2.69 to 8.8) 
Leptin (ng/ml); n=481 12.4 (3.7 to 43.8) 
Quality of Life Domains; median (25th to 75th percentiles) 
     SF-36 Physical functioning; n=457 
     SF-36 Vitality; n=457 
     FACIT Fatigue; n=572 
 
70 (50 to 85) 
55 (40 to 75) 
73.1 (57.7 to 86.3) 
  
 Figure 1A and Figure 1B illustrate the distribution of baseline troponin T and NT-
proBNP levels. As is demonstrated in Figure 1 A and B, only a small portion of the study 
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population had elevated cardiac biomarker levels at baseline. The upper quartile for troponin 
T was > 0.051 ng/ml (N=118) and for NT-proBNP it was >652 pg/ml (N=120).  
 
 
Figure 1A: Distribution of baseline troponin T levels in hemodialysis patients 
without prior symptomatic cardiac disease. Troponin T levels are expressed in units 
of ng/mL. 
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Figure 1B: Distribution of baseline NT-proBNP levels in hemodialysis patients without 
prior symptomatic cardiac disease. NT-proBNP levels are expressed in units of pg/mL 
 
Figure 2 demonstrates the serial scores for quality of life in SF-36 Physical 
Function, SF-36 Vitality, and FACIT Fatigue at baseline, 24, 48 and 96 weeks. As 
signified by the graph, the quality of life scores deteriorated over the course of the 96-
week study, however on average the changes were very slight. There was however 
noteworthy variation in quality of life scores at each time point, which is represented in 
the interquartile range (IQR). The median score for physical function at baseline was 70 
with an interquartile range (IQR) of 50-85, for vitality it was 55 (IQR 40-75) and for 
fatigue it was 73.1 (IQR 57.7-86.3). At 24 weeks the median score for physical function 
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was 70 (IQR 50-90), for vitality it was 57.5 (IQR 40-75), and for fatigue it was 75 (IQR 
55.8-86.5). At 48 weeks the median score for physical function was 70 (IQR 50-90), for 
vitality it was 55 (IQR 40-75), and for fatigue it was 73.1 (IQR 55.8-86.5). At 96 weeks 
the median score for physical function was 70 (IQR 45-90), for vitality it was 55 (IQR 
40-75), and for fatigue it was 72.9 (IQR 53.8-88.5).   
	  
Figure 2: Serial HRQOL scores for SF-36 domains physical function and vitality, and 
for FACIT fatigue, in hemodialysis patients without symptomatic cardiac disease. 
 
Table 2A and Table 2B show the significant univariate and multivariate 
associations between high troponin T levels at baseline and baseline clinical 
characteristics and biomarkers. The independent and significant predictors of elevated 
troponin levels were male sex (p<0.001), older age (p<0.05), diabetes (p<0.001), high 
lactate dehydrogenase (p<0.05) and high NT-proBNP levels (p<0.001). 
	  	  
	  
35	  
Table 2A: Significant univariate associations between baseline Troponin T levels 
and baseline clinical characteristics, using linear regression 
Characteristic     Reference Unadjusted 
B Coefficient 
95% C.I. 
  
Sex Male 0.52 0.33 to 0.82** 
Age Per 1 year  1.03 1.01 to 1.04** 
Diabetes No Diabetes 4.59 2.81 to 7.48*** 
LV Mass Index 1 g/m2 1.01 1.01 to 1.02*** 
Hb < 11.1 g/dL 0.52 0.33 to 0.80** 
Serum Albumin < 40 g/L 0.56 0.36 to 0.88* 
Lactate 
Dehydrogenase 
Per 1 U/L 1.02 1.01 to 1.02*** 
Potassium Per 1 mmol/L 1.36 1.03 to 1.79* 
White Blood Cells < 8.1 x 109/L 1.84 1.15 to 2.95* 
Platelet Count < 260 x 109/L 1.73 1.09 to 2.75* 
NT-proBNP < 651.9 pg/ml 4.00 2.55 to 6.28*** 
*p<0.05;**p<0.01;***p<0.001.                                                                                                      
Unadjusted B coefficient was calculated using univariate linear regression (column 3 & 4).       
 
Table 2B: Significant multivariate associations between baseline Troponin T levels 
and baseline clinical characteristics, using linear regression 
Characteristic     Reference Adjusted B 
Coefficient 
95% C.I. 
Sex Male 0.38 0.22 to 0.67*** 
Age Per 1 year  1.02 1.00 to 1.04* 
Diabetes No Diabetes 4.62 2.55 to 8.38*** 
Lactate 
Dehydrogenase 
Per 1 U/L 1.01 1.00 to 1.02* 
NT-proBNP < 651.9 pg/ml 3.53 2.04 to 6.13*** 
*p<0.05;**p<0.01;***p<0.001.                                                                                                          
Adjusted B coefficient was calculated using multivariate linear regression to identify the significant 
and independent predictors (column 5 & 6). 
 
Table 3A and Table 3B show the significant univariate and multivariate 
associations between baseline clinical variables and biomarkers and baseline health-
related quality of life scores. The univariate models for SF-36 Physical Functioning show 
significance for a multitude of factors, however the multivariate model revealed that the 
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significant, independent variables associated with improved physical functioning scores 
were younger age (p<0.01), presence of a fistula as vascular access (p<0.01) and lower 
NT-proBNP levels (p<0.05). For SF-36 Vitality, the multivariate models only showed a 
significant association for a higher urea reduction ratio (p<0.05) with improved vitality. 
The sole variable with a significant association with improved scores on the FACIT 
Fatigue scale was a higher URR (p<0.01) based on the multivariate models. Model 
performance was assessed using R2, which quantifies how much variance in the 
dependent variable is explained by the independent predictors. For SF-36 Physical 
Functioning, 21.5% (R2= 0.215) of the variance in the baseline quality of life can be 
explained by the multivariate model. When the cardiac biomarkers were removed from 
the model, the adjusted R2 value decreased, thus worsening the model. For SF-36 Vitality, 
R2= 0.066, meaning a smaller percentage of variation was explained by the model. 
Neither cardiac biomarker was included in the original multivariate model and when they 
were added the adjusted R2 value decreased thus indicating a worse predictive model. The 
R2 for FACIT Fatigue was 0.052, indicating 5.2% of the variance in quality of life being 
explained by the multivariate model. Similarly for Fatigue, the inclusion of the cardiac 
biomarkers did not improve the adjusted R2 value.  
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Table 3A: Significant univariate associations between baseline clinical variables and 
biomarkers and baseline HRQOL scores using linear regression 
Characteristic       Reference Unadjusted B 
Coefficient 
95% C.I. 
SF-36 Physical Functioning    
Female Male -7.56 -12.30 to -2.81**   
Age per 1 year -0.49 -0.63 to -0.35** 
Body Mass Index per 1 kg/m2 -0.63 -1.05 to -0.20** 
Diabetes No Diabetes -8.25 -14.27 to -2.23** 
Fistula No Fistula 12.52 6.54 to 18.51** 
Serum Albumin < 40 g/L 6.36 1.54 to 11.18** 
Serum Creatinine per 1 umol/L 0.02 0.01 to 0.03** 
Sodium per 1 umol/L 0.76 0.06 to 1.46* 
White Blood Cells < 8.1 x 109/L -7.98 -13.60 to -2.37** 
Neutrophils < 68% -7.33 -12.90 to -1.77** 
Leptin per 1 ng/ml -0.17 -0.26 to -0.08** 
Troponin T < 0.051 ng/ml -9.54 -15.60 to -3.48** 
NT-proBNP < 651.9 pg/ml -6.05 -12.11 to 0.01* 
IL-6 per 1 pg/ml -0.19 -0.38 to -0.01* 
    
SF-36 Vitality    
Female Male -5.73 -9.88 to -1.58** 
Urea Reduction Ratio < 60% 8.58 3.52 to 13.64** 
White Blood Cells < 8.1 x 109/L -6.76 -11.62 to -1.91** 
Leptin per 1 ng/ml -0.09 -1.17 to -0.01* 
C-Reactive Protein per 1 mg/L -0.18 -0.35 to -0.00* 
    
FACIT Fatigue    
Female Male -5.00 -8.26 to -1.73** 
Body Mass Index per 1 kg/m2 -0.30 -0.60 to 0.00* 
Diabetes No Diabetes -5.07 -9.40 to -0.73* 
Urea Reduction Ratio < 60% 6.75 3.04 to 10.47** 
Leptin per 1 ng/ml -0.10 -0.17 to -0.04** 
*p<0.05; **p<0.01                                                                                                                           
Unadjusted B coefficient was calculated using univariate linear regression (column 3 & 4).      
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Table 3B: Significant multivariate associations between baseline clinical variables 
and biomarkers and baseline HRQOL scores using linear regression 
Characteristic       Reference Adjusted B 
Coefficient 
95% C.I. 
SF-36 Physical Functioning    
Female Male   
Age per 1 year -0.38 -0.56 to -0.20** 
Fistula No Fistula 10.69 3.52 to 17.86** 
NT-proBNP < 651.9 pg/ml -6.33 -12.40 to -0.26* 
 
SF-36 Vitality 
   
Urea Reduction Ratio < 60% 6.33 0.48 to 12.17* 
    
FACIT Fatigue    
Urea Reduction Ratio < 60% 5.61 1.42 to 9.81** 
*p<0.05; **p<0.01                                                                                                                               
Adjusted B coefficient was calculated using multiple linear regression to identify the significant and 
independent predictors (column 5 & 6). 
 
Table 4A and Table 4B show the significant univariate and multivariate 
associations between baseline clinical variables and biomarkers and short-term change 
(24 weeks) and long-term change (48 & 96 weeks) in HRQOL for the three specified 
domains.  
For the SF-36 Vitality domain, the multivariate model showed significance 
between being in the higher hemoglobin target group (p<0.05) and having a lower platelet 
count (p<0.05) with an improved short term change in quality of life. The multivariate 
models revealed a significant association between a lower URR (p<0.01), a higher serum 
calcium (p<0.01), a lower platelet count (p<0.05) and a higher Epo dose (p<0.01) with 
improved quality of life over 48 weeks. These appear to be relatively random associations 
with little biologic rationale. The multivariate models showed elevated troponin T levels 
to be significantly associated with worsening vitality over 96 weeks (p<0.05). The R2 
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value for the multivariate model assessing change at 24 weeks was 0.028, which didn’t 
include the cardiac biomarkers. When the cardiac biomarkers were added to the model, 
the adjusted R2 value increased, indicating better model performance, however the 
individual cardiac biomarkers were not significantly associated with the change in quality 
of life. This trend was seen in both the change at 48 weeks model, as well as the change at 
96 weeks. The R2 value for multivariate model assessing change at 48 weeks was 0.080, 
and for change at 96 weeks it was 0.038, thus indicating that a relatively small amount of 
the variance seen in vitality is explained by the multivariate models. 
For SF-36 Physical Functioning, having an elevated platelet count was 
significantly associated with deterioration in quality of life over 24 weeks (p<0.01). The 
multivariate models for long-term change in quality of life showed higher serum calcium 
(p<0.05) and lower troponin T levels (p<0.05) to be significantly associated with 
improved quality of life over 48 weeks, and the presence of diabetes to be significantly 
associated with deteriorating physical functioning over 96 weeks (p<0.05).  It is important 
to note the potential of confounding for this analysis, as the patients with higher calcium 
levels will also have higher albumin levels, so although serum calcium was associated 
with change in quality of life, it is possible that it is masking the true marker, serum 
albumin. The R2 value for change at 24 weeks was 0.032, for change at 48 weeks was 
0.033 and for change at 96 weeks was 0.061. When the both cardiac biomarkers were 
included in the model, the adjusted R2 value increased at 24 weeks and 96 weeks, thus 
indicating better model performance, despite the individual cardiac biomarkers not be 
significantly associated. At 48 weeks however, when NT-proBNP was included in the 
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model the adjusted R2 value decreased, indicating worsened model performance. 
Similarly to SF-36 Vitality, only a small proportion of the variance in quality of life 
scores are explained by the multivariate models. 
The multivariate models revealed a significant association between elevated 
troponin T levels (p<0.05) and worsened FACIT Fatigue scores over 24 weeks. Long-
term change deterioration in fatigue scores over 48 weeks was significantly associated 
with lower serum creatinine (p<0.05), and an elevated platelet count (p<0.05). No 
significant associations were found over 96 weeks for FACIT Fatigue. The R2 value for 
change in fatigue at 24 weeks was 0.028, for change at 48 weeks was 0.028 and for 
change at 96 weeks was 0.029. When the both cardiac biomarkers were included in the 
multivariate model, the adjusted R2 value decreased at 24, 48 and 96 weeks indicating a 
worsened model performance. Similarly to the other two domains of quality of life, only a 
small proportion of the variance in fatigue scores are explained by the multivariate 
models, indicating that other factors are significantly influencing these patient’s quality of 
life. 
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Table 4A: Significant univariate associations between baseline clinical variables and 
biomarkers and change in short-term and long-term HRQOL scores, using linear 
regression 
Characteristic          Reference 
  
Unadjusted B 
Coefficient 
95% C.I. 
SF-36 Physical 
Functioning 
   
Change at 24 wks    
LV Mass Index per 1 g/m2 -0.06 -0.12 to -0.00* 
Serum Calcium < 2.42 mmol/L 4.25 0.02 to 8.47* 
Platelet Count < 260 x 109/L -5.54 -9.95 to -1.13 
Change at 48 wks    
Serum Calcium < 2.42 mmol/L 6.63 1.61 to 11.66** 
Troponin T < 0.051 ng/ml -6.40 -12.62 to -0.18* 
Change at 96 wks    
Diabetes No Diabetes -7.28 -14.07 to -0.49* 
Troponin T < 0.051 ng/ml -9.43 -16.44 to -2.42** 
    
SF-36 Vitality    
Change at 24 wks    
High Hb Group Low Hb Group 5.09 1.16 to 9.03* 
Platelet Count < 260 x 109/L -5.00 -9.63 to -0.38* 
Change at 48 wks    
Urea Reduction Ratio < 60% -6.97 -12.22 to -1.72** 
Serum Calcium < 2.42 mmol/L 5.34 0.94 to 9.73* 
Platelet Count < 260 x 109/L -5.93 -10.67 to -1.18* 
Epo dose < 6000 U/wk 5.25 1.07 to 9.43* 
Change at 96 wks    
Fractional shortening per 1% -0.32 -0.62 to -0.02* 
Troponin T < 0.051 ng/ml -7.55 -14.18 to -0.91* 
    
FACIT Fatigue    
Change at 24 wks    
Lactate dehydrogenase per 1 U/L  -0.05 -0.09 to -0.00* 
White blood cells < 8.1 x 109/L -4.32 -8.19 to -0.46* 
Troponin T < 0.051 ng/ml -5.38 -9.37 to -1.38** 
Change at 48 wks    
Serum Creatinine per 1 umol/L 0.01 0.00 to 0.02** 
Platelet Count < 260 x 109/L -5.06 -9.20 to -0.93* 
Change at 96 wks    
Epo Dose < 6000 U/wk -5.11 -9.92 to -0.31* 
*p<0.05; **p<0.01                                                                                                                           
Unadjusted B coefficient was calculated using univariate linear regression (column 3 & 4).       
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Table 4B: Significant multivariate associations between baseline clinical variables 
and biomarkers and change in short-term and long-term HRQOL scores, using 
linear regression 
Characteristic          Reference 
  
Adjusted B 
Coefficient 
95% C.I. 
SF-36 Physical 
Functioning 
   
Change at 24 wks    
Platelet Count < 260 x 109/L -5.93 -10.37 to -1.50** 
Change at 48 wks    
Serum Calcium < 2.42 mmol/L 6.00 0.39 to 11.62* 
Troponin T < 0.051 ng/ml -6.70 -12.93to -0.47* 
Change at 96 wks    
Diabetes No Diabetes -8.84 -16.61 to -1.07* 
    
SF-36 Vitality    
Change at 24 wks    
High Hb Group Low Hb Group 5.11 1.07 to 9.14* 
Platelet Count < 260 x 109/L  -9.58 to -0.40* 
Change at 48 wks    
Urea Reduction Ratio < 60% -7.06 -12.35 to 1.77** 
Serum Calcium < 2.42 mmol/L 6.18 1.62 to 10.74** 
Platelet Count < 260 x 109/L -5.01 -9.84 to -0.18* 
Epo dose < 6000 U/wk 5.73 1.53 to 9.93** 
Change at 96 wks    
Troponin T < 0.051 ng/ml -7.09 -13.73 to -0.46* 
    
FACIT Fatigue    
Change at 24 wks    
Troponin T < 0.051 ng/ml -4.91 -9.09 to -0.74* 
Change at 48 wks    
Serum Creatinine per 1 umol/L 0.01 0.00 to 0.02* 
Platelet Count < 260 x 109/L -4.78 -8.92 to -0.63* 
Change at 96 wks    
*p<0.05; **p<0.01                                                                                                                               
Adjusted B coefficient was calculated using multiple linear regression to identify the significant and 
independent predictors (column 5 & 6). 
           
           Table 5 shows the unadjusted and adjusted B coefficients for baseline troponin T 
levels and baseline HRQOL scores and change in quality of life over time from the 
univariate and multivariate analysis. In the unadjusted, univariate models elevated 
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troponin T is significantly associated with lower physical functioning at baseline, 48 
weeks, and 96 weeks, with deteriorating vitality at 96 weeks and deteriorating fatigue at 
24 weeks (approaches significance at 96 weeks). In the multivariate model controlling for 
other significant variables, elevated troponin T levels were significantly associated with 
deteriorating physical functioning at 48 weeks (approaches significance at 96 weeks), 
deteriorating vitality at 96 weeks and worsening fatigue at 24 and 96 weeks. When 
controlling for age, sex, diabetes status and baseline QoL score, high troponin T levels 
were associated with worsening physical functioning over 24, 48 and 96 weeks, with 
deteriorating vitality over 96 weeks and with worsening fatigue levels over 24 weeks. 
Examination of the unadjusted and adjusted B coefficients suggests consistent impact of 
baseline troponin T levels on change in HRQOL. 
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Table 5: Summary of the unadjusted and adjusted B coefficients for baseline 
Troponin T levels and baseline HRQOL scores and change in these scores over time 
  Unadjusted 
B 
p value Adjusted 
B* 
p value* Adjusted 
B** 
p value** 
SF-36 Physical 
Functioning 
      
Baseline  -9.54 0.002 -5.92 0.071   
Change at 24 wks -4.13 0.111   -6.02 0.018 
Change at 48 wks -6.40 0.044 -6.70 0.035 -8.09 0.008 
Change at 96 wks -9.43 0.009 -7.60 0.056 -8.42 0.015 
       
SF-36 Vitality       
Baseline -1.56 0.571     
Change at 24 wks -3.46 0.182   -3.23 NS 
Change at 48 wks -1.36 0.633   -1.36 NS 
Change at 96 wks -7.55 0.026 -7.09 0.036 -7.10 0.037 
       
FACIT Fatigue       
Baseline -1.58 0.465     
Change at 24 wks -5.38 0.008 -4.91 0.021 -5.95 0.002 
Change at 48 wks -3.89 0.093   -4.22 NS 
Change at 96 wks -5.46 0.057 -6.19 0.035 -4.56 NS 
*Adjusted for other variables with p<0.05.                                                                                  
**Adjusted for age, sex, diabetes status and baseline QoL score.                                             
Unadjusted B coefficient was calculated using univariate linear regression.                               
Adjusted B coefficient was calculated using multivariate linear regression. 
             
            Table 6 shows the unadjusted and adjusted B coefficients for baseline NT-proBNP 
levels and baseline HRQOL scores and change in quality of life over time from the 
univariate and multivariate analysis. In the unadjusted, univariate models elevated NT-
proBNP is significantly associated with less good physical functioning at baseline. The 
effect persisted in the multivariate model controlling for other significant variables. These 
are the only significant associations between elevated NT-proBNP and quality of life, 
indicating no significant relationship or predictive value of deterioration in quality of life 
over time.  
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Table 6: Summary of the unadjusted and adjusted B coefficients for baseline NT-
proBNP levels and baseline HRQOL scores and change in these scores over time 
  Unadjusted 
B 
p value Adjusted 
B* 
p value* Adjusted 
B** 
p value** 
SF-36 Physical 
Functioning 
      
Baseline  -6.05 0.05 -6.33 0.041   
Change at 24 wks 2.09 0.429     
Change at 48 wks 0.57 0.864     
Change at 96 wks 5.18 0.164     
       
SF-36 Vitality       
Baseline -1.28 0.641     
Change at 24 wks 0.64 0.810     
Change at 48 wks 4.20 0.157     
Change at 96 wks -4.08 0.241     
       
FACIT Fatigue       
Baseline -2.13 0.318     
Change at 24 wks -0.76 0.713     
Change at 48 wks -1.96 0.409     
Change at 96 wks -3.44 0.242     
*Adjusted for other variables with p<0.05.                                                                                  
**Adjusted for age, sex, diabetes status and baseline QoL score.                                             
Unadjusted B coefficient was calculated using univariate linear regression.                               
Adjusted B coefficient was calculated using multivariate linear regression. 
 
Table 7 shows the significant associations for the repeated measures ANOVA of 
the three health-related quality of life domains of interest. For SF-36 Physical Function, 
age, baseline physical function score, sex, troponin T, the interaction of sex and troponin, 
and the interaction of diabetes and troponin, were all significantly associated with the 
repeated measures of physical functioning over time. Of these variables baseline physical 
function score and troponin T had the highest level of significance with a p<0.001. For 
the SF-36 Vitality domain only baseline vitality score was significantly associated with 
the repeated measures score however troponin T approaches significance with a p=0.06. 
For the repeated measures of FACIT Fatigue, baseline fatigue score, sex and troponin T 
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were all significantly associated with the repeated measures score, with baseline fatigue 
score having the greatest degree of significance (p<0.001). 
 
Table 7: Significant associations for repeated measures ANOVA of quality of life 
scores and baseline clinical characteristics 
Characteristic     F Sig 
SF-36 Physical Function   
Age 5.869 0.016 
Baseline Physical Function Score 52.358 <0.001 
Sex 4.945 0.027 
Troponin T 13.682 <0.001 
Sex * Troponin T 5.420 0.021 
Diabetes * Troponin T 5.382 0.022 
   
SF-36 Vitality   
Baseline Vitality Score 34.170 <0.001 
Troponin T 3.580 0.060 
   
FACIT Fatigue   
Baseline Fatigue Score 65.901 <0.001 
Sex 3.923 0.049 
Troponin T 4.289 0.040 
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Chapter 5: Discussion 
The current study examined the predictive value of cardiac biomarkers for 
deteriorating quality of life in new hemodialysis patients without symptomatic 
cardiovascular disease. The major conclusions from this paper were: that health-related 
quality of life scores for physical function, vitality and fatigue in this relatively healthy 
hemodialysis population were closer to the general population scores than unselected 
hemodialysis patients, and these scores changed minimally over 2 years on average; only 
a small minority of patients had elevated baseline troponin T levels and these high levels 
were significantly associated with elevated NT-proBNP independent of age, sex, diabetes; 
high baseline troponin T levels were significantly associated with a deterioration in 
quality of life in physical function, vitality and fatigue domains over the short and long 
term, however NT-proBNP levels were not. 
5.1 Health-related quality of life 
 Patients suffering from end-stage renal disease have consistently lower quality of 
life scores, particularly in physical function and vitality, when compared to healthy 
matched controls without end-stage renal disease (Spiegel et al., 2008). In patients with 
ESRD who are receiving dialysis, the average score for SF-36 physical function is 41 
compared to 86 in the general healthy population (Hopman et al., 2000; Fukuhara et al., 
2003). This impaired quality of life is maintained for SF-36 vitality, with dialysis patients 
reporting an average score of 43 (Fukuhara et al., 2003) as compared to 66 in the general 
population (Hopman et al., 2000), and for FACIT Fatigue as diabetic dialysis patients 
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report a score of 30 compared to 80 in the general population (Lewis et al., 2011). As 
indicated, the presence of end-stage renal disease results in severe and drastic declines in 
patient reported quality of life. The dialysis populations used to generate these statistics 
are uncontrolled for comorbidities and conditions that may be impacting the patient’s 
quality of life. Patients in these populations may be suffering from cardiovascular disease, 
diabetes or some other comorbidity that is significantly impacting their day-to-day life 
resulting in poor self reported health related quality of life. 
 In this study, the study participants were selected using explicit inclusion and 
exclusion criteria to ensure a relatively “healthy” hemodialysis population. Participants 
were all new hemodialysis patients, with no left ventricular dysfunction as indicated by a 
LV volume index < 100 ml/m2, and a predialysis diastolic blood pressure < 100 mmHg. 
Any patients with clinical evidence of symptomatic heart failure or ischemic heart disease 
or concurrent malignancy were excluded. As a result of these inclusion/exclusion criteria 
a relatively “healthy” study population was identified with an average quality of life score 
closer to the general population than to the unselected dialysis population. The “health” 
status of this population is further confirmed by the observation of an annual mortality of 
5%, which is substantially lower than that in unselected hemodialysis patients (Parfrey et 
al., 2005). The median score for SF-36 physical function for the study population was 67, 
for SF-36 vitality was 58 and for FACIT Fatigue was 70 (Foley et al., 2009). As 
previously discussed, the “healthy” study participants more closely resemble the general 
population, leading to the conclusion that there are comorbidities amongst end-stage renal 
disease patients that severely deteriorate their quality of life. The presence of 
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symptomatic cardiovascular disease is one such comorbidity as there is a clear association 
between the presence of cardiac disease and health-related quality of life in dialysis 
patients. The presence of cardiovascular disease in end-stage renal disease patients 
accounts for approximately 50% of deaths amongst patients on maintenance hemodialysis 
(Henrich, 2014) and leads to a mortality rate that is roughly 10 to 100-times higher than 
age, gender and race matched controls (Wang & Lam, 2012).  
5.2 Baseline elevations in troponin T and NT-proBNP and associations with change 
in health-related quality of life 
 Hemodialysis patients who have not experienced cardiovascular events may have 
elevated cardiac markers (troponin T and NT-proBNP) that may be predictive for later 
outcomes (Foley et al., 2010). In the study population, there was a substantial minority of 
participants who had elevated troponin T and NT-proBNP levels at baseline, an expected 
result given the overall health of the study population.  
Troponin T is a biomarker with strong prognostic value for all-cause mortality and 
cardiovascular outcomes in end-stage renal disease patients (Khan et al., 2005). In a study 
by Apple et al., elevated cardiac troponin T was defined as greater than the 99th percentile 
of healthy reference population, > 0.01 ng/ml, with 82% of an unselected hemodialysis 
population asymptomatic for cardiovascular disease having an elevated level using this 
cut-off (Apple et al., 2002). A study by Wang et al. demonstrated that even minimally 
increased troponin T levels (between 0.01-0.1 ng/ml) have increased risk for mortality 
and adverse cardiovascular events compared to those with undetectable levels (Wang et 
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al., 2007). Elevated troponin T >0.1 ng/ml typically identifies the sickest patients and 
those with poor survival and the higher risk of death (Khan et al., 2005; Wang et al., 
2007). In a previous study by Foley et al. using the same population of patients as the 
current study, it was reported that higher troponin T levels were predictive of subsequent 
cardiovascular events or death in the study cohort, but elevated troponin T levels are not 
independent of age, diabetes, systolic blood pressure or NT-proBNP (Foley et al., 2010). 
In our study, the median value for troponin T is 0.021 ng/ml with an interquartile range of 
0.009 to 0.051 ng/ml. Elevated troponin T levels for our population were defined by the 
75th percentile, > 0.051 ng/ml. Research from Wang & Lam suggests that elevated 
troponin T levels in hemodialysis patients reflect not only myocardial injury and ischemia 
but myocardial fibrosis as well (Wang & Lam, 2012). This, coupled with results from the 
current study, supports the notion that high troponin levels are not innocuous and that 
they are significantly associated with deterioration in health-related quality of life. It is 
currently not possible to determine whether this deterioration of quality of life is the result 
of subsequent cardiac events, or due to a baseline degree of myocardial injury present at 
the commencement of the study. The latter hypothesis is supported by the fact only 4% of 
patients proceeded to a cardiovascular event (myocardial infarction, myocardial ischemia, 
angina pectoris, cardiac failure, pulmonary edema, cerebellar infarction, cerebral 
haemorrhage, cerebral vascular disorder, or death) by six months (Foley et al., 2010). 
Furthermore, high troponin T levels were associated with deteriorating quality of life 
scores at baseline and after short-term follow up across all three domains of interest 
(Table 4). This lends support to the notion of a baseline level of myocardial injury in 
hemodialysis patients in the pre-symptomatic phase of cardiac disease, as manifested by 
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raised serum troponin levels in patients without symptomatic cardiac disease. This may 
indicate an increased risk of having adverse clinical consequences, revealed by the 
association with lower quality of life scores in physical domains. More investigation is 
required however before this hypothesis can be confirmed. 
N terminal pro-type B natriuretic peptide is a cardiac biomarker that reflects left 
ventricular wall stress that can occur secondary to volume expansion, pressure overload 
and increased wall tension. This biomarker is strongly influenced by renal disease, with 
increasing concentrations found among dialysis patients with end-stage renal disease 
(Wang & Lam, 2012). In a study by Apple et al., the normal cutoff for NT-proBNP was 
the 97.5th percentile, 125 ng/L for patients younger than 75 years, and 450 ng/L for 
patients older than 75 years (Apple et al., 2004). In our study population the median value 
for NT-proBNP was 289.2 pg/mL, with an elevated NT-proBNP level being defined as 
greater than 651.9 pg/mL (75th percentile). Previously in the current study population, it 
was indicated that NT-proBNP levels were independently predictive for baseline LVMI, 
of increasing LVMI over time and the resulting occurrence of adverse cardiovascular 
events, however it was unclear whether the BNP relationship was the result of left 
ventricular volume overload or underlying cardiac dysfunction (Foley et al., 2010). While 
elevated NT-proBNP levels may be associated with left ventricular hypertrophy and 
systolic dysfunction in some populations, in hemodialysis patients who are stable with 
normal left ventricular function on echocardiography and without a prior history of 
symptomatic cardiovascular disease, high BNP levels are likely the result of blood 
volume expansion and require reduction in post dialysis “dry” weight (Parfrey, 2010). 
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While NT-proBNP is predictive for mortality in hemodialysis patients (Madsen et al., 
2007), elevated levels were not consistently associated with a deterioration in health-
related quality of life across the three domains of interest at baseline, in the short term or 
in long term follow-up (Table 5).  
5.3 Future Research Directions 
The results of this study suggest that further research is required examining 
markers for cardiovascular disease as predictors for quality of life in hemodialysis 
patients. Prior research by Foley et al. conducted on the same clinical trial population as 
this study found an association between BNP and left ventricular mass index (Foley et al., 
2010). Given that serial echocardiography data is available from this prior research, and it 
is believed from this research that troponin T is marking sub-clinical cardiac disease, 
further analysis could examine whether changes in parameters of left ventricular structure 
and/or function over time have any association with health-related quality of life.  
5.4 Study limitations 
  This study is a continuation of research published by Parfrey et al. examining the 
full and partial correction of anemia in hemodialysis patients without symptomatic 
cardiovascular disease (Parfrey et al., 2005). The original study was a double blind 
randomized control trial carried out over a 2-year period, during which patients were 
randomized to a target haemoglobin level that was achieved and maintained by 
erythropoietin. The measurement of baseline cardiac biomarkers and health-related 
quality of life scores were a secondary objective. Resultantly, the study from which the 
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data originated was not designed to properly assess the predictive value of cardiac 
biomarkers for health related quality of life over time. Cardiac biomarker levels were 
recorded at baseline and analyzed to assess their association with change in quality of life. 
Given that quality of life was measured at 0, 24, 48 and 96 weeks, but TNT and NT-
proBNP only at baseline, it is not possible to account for the impact that the study 
procedures and hemoglobin levels had on the cardiac biomarkers and subsequent quality 
of life scores over the duration of the study.   
The patients studied in the original trial were monitored for the duration of the 
study for adverse cardiovascular events including myocardial infarction, myocardial 
ischemia, angina pectoris, cardiac failure, pulmonary edema, cerebellar infarction, 
cerebral haemorrhage, cerebral vascular disorder, or death (Parfrey et al., 2005). It was 
not possible however to confirm that the deteriorating health-related quality of life scores 
occurred solely as the result of elevated troponin T, independent of an adverse 
cardiovascular event, or if the elevated troponin levels were marking for a subsequent 
adverse event that resulted in the decreased quality of life. The confounding was limited 
due to the exclusion of patients with prior symptomatic cardiovascular disease and 
echocardiographic systolic dysfunction, but the potential for a confounding influence still 
exists, despite best efforts to minimize it’s effect. 
 All study participants received the SF-36, FACIT Fatigue, and KDQOL 
instruments to asses health-related quality of life at 0, 24, 36, 48, 60, 72, 84 and 96 weeks 
of the study. At baseline however only 457 patients were included for the SF-36 Physical 
Functioning & SF-36 Vitality and 572 were included for the FACIT Fatigue (Parfrey et 
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al., 2005). It is possible that patients who did not have repeat measurements of HRQOL 
may be systematically different than the measured population. This systematic difference 
however would likely result in an underestimation of the true association between 
biomarkers and HRQOL.  
The pre-determined statistical plan included dichotomization of both troponin T 
and BNP levels because they were not normally distributed. Further analysis of these 
biomarkers as a continuous variable with transformation to tame distributional anomalies 
could be undertaken to strengthen the validity and significance of the statistical analysis. 
Missing data was handled using listwise deletion, a technique with a number of 
drawbacks including a decreased sample size or loss of data for the statistical analysis, 
which could impact the power and significance of the results, and the potential of 
producing bias in the parameters and estimates. It is important to note that the missing 
value points for this study were assumed to be random and as a result the population 
included in the analysis is believed to be representative of the study population, however 
the statistical analysis could have been strengthened if the pattern of missing values was 
examined and confirmed to be random. This would allow the magnitude and direction of 
bias introduced by the pattern of missing variables to be assessed, which would have 
enhanced the power of the analysis. While a number of alternative methods were 
considered for dealing with the missing values, it was determined that listwise deletion 
was appropriate given the number of missing cases in the population and the assumption 
that these missing values were random. The number of subjects included for each analysis 
was examined for all univariate and multivariate models to ensure adequate sample size 
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but it is inevitable that power and significance will be negatively impacted by the missing 
data. This is particularly true for the repeated measures ANOVA, as any missing data 
point in one of the time intervals would cause the entire subject to be rejected from the 
analysis, impacting the significance of the findings. There is also the potential for Type 1 
error given the number of comparisons that were made in the univariate and multivariate 
models, which could produce inappropriate and false associations between clinical 
characteristics and quality of life. It is possible that some of the associations that had little 
biologic rationale and appeared random could be the result of such an error.    
5.5 Conclusion 
 In conclusion, in a group of incident hemodialysis patients without prior history of 
symptomatic cardiovascular disease, elevated troponin T levels at baseline were 
associated with deterioration in SF-36 Physical Function, SF-36 Vitality and FACIT 
Fatigue over time. In the same group of incident hemodialysis patients there was no 
detectable association between elevated NT-proBNP levels and deteriorating quality of 
life in any of three specified domains over time.  
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